Takeda Pharmaceutical Company Limited (TAK) Stock Score, Valuation & Financial Research
Takeda Pharmaceutical Company Limited is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 26/100.
Quick answer for TAK
Takeda Pharmaceutical Company Limited currently has a Wall Street Score of 26/100. The stored market price is $18.11. Its financial score is 19/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Takeda Pharmaceutical Company Limited does
Takeda Pharmaceutical Company Limited is a prominent global biopharmaceutical entity dedicated to the discovery, development, manufacturing, commercialization, and out-licensing of pharmaceutical products. The company's operations extend across a vast international footprint, encompassing Japan, the United States, Europe, Canada, Latin America, Russia, and numerous other Asian and worldwide markets. Its extensive portfolio of medicines targets critical therapeutic areas, including digestive disorders (gastroenterology), rare diseases, plasma-derived treatments, cancer care (oncology), and neurological conditions. Takeda markets these products under various well-recognized brand names, such as Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velca
TAK financial snapshot
- Wall Street Score:
- 26/100
- Current price:
- $18.11
- Market capitalization:
- $57.63B
- Revenue:
- $27.78B
- Net income:
- $1.18B
- Free cash flow:
- $4.94B
- Cash:
- $3.65B
- Total debt:
- $29.95B
- EPS:
- 0.39
- P/E ratio:
- 46.4x
- Financial score:
- 19/100
- Valuation score:
- 4/100
- Revenue score:
- 14/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $4.94B, showing positive cash generation.
- The balance sheet shows $3.65B of cash versus $29.95B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 19/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TAK
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.